JP2024518536A5 - - Google Patents

Info

Publication number
JP2024518536A5
JP2024518536A5 JP2023570108A JP2023570108A JP2024518536A5 JP 2024518536 A5 JP2024518536 A5 JP 2024518536A5 JP 2023570108 A JP2023570108 A JP 2023570108A JP 2023570108 A JP2023570108 A JP 2023570108A JP 2024518536 A5 JP2024518536 A5 JP 2024518536A5
Authority
JP
Japan
Prior art keywords
approximately
optionally
formulation
proline
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/029043 external-priority patent/WO2022241148A1/en
Publication of JP2024518536A publication Critical patent/JP2024518536A/ja
Publication of JP2024518536A5 publication Critical patent/JP2024518536A5/ja
Pending legal-status Critical Current

Links

JP2023570108A 2021-05-12 2022-05-12 抗体組成物 Pending JP2024518536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187476P 2021-05-12 2021-05-12
US63/187,476 2021-05-12
PCT/US2022/029043 WO2022241148A1 (en) 2021-05-12 2022-05-12 Antibody composition

Publications (2)

Publication Number Publication Date
JP2024518536A JP2024518536A (ja) 2024-05-01
JP2024518536A5 true JP2024518536A5 (enExample) 2025-05-16

Family

ID=82156644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570108A Pending JP2024518536A (ja) 2021-05-12 2022-05-12 抗体組成物

Country Status (8)

Country Link
US (1) US20240216506A1 (enExample)
EP (1) EP4337257A1 (enExample)
JP (1) JP2024518536A (enExample)
KR (1) KR20240021800A (enExample)
CN (1) CN117615788A (enExample)
AU (1) AU2022274319A1 (enExample)
CA (1) CA3218343A1 (enExample)
WO (1) WO2022241148A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
SI2523688T1 (en) * 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
WO2013123114A2 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
US10526410B2 (en) * 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
PL3615066T3 (pl) * 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
KR20210119407A (ko) * 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
CR20210373A (es) * 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
US11730812B2 (en) * 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
IL298989A (en) * 2020-07-03 2023-02-01 CSL Innovation Pty Ltd High concentration promotion of factor XII antigen binding proteins
JP2023553538A (ja) * 2020-12-14 2023-12-21 エーマックス バイオ， インコーポレイテッド 抗ｃｓｆ１および抗ｃｓｆ１ｒ抗体の高濃度製剤
US20240002517A1 (en) * 2020-12-16 2024-01-04 CSL Innovation Pty Ltd Protein formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2024016177A5 (enExample)
JP2023515271A5 (enExample)
JP2020518599A5 (enExample)
JP2020518600A5 (enExample)
HRP20240182T1 (hr) Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
JP2024075713A5 (enExample)
JP2020509031A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2019523295A5 (enExample)
JP2020500538A5 (enExample)
JP2011528902A5 (enExample)
RU2011128332A (ru) Антитело против siglec-15
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
JP2011506483A5 (enExample)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
CA2707400A1 (en) Method for treating bone fracture with anti-sclerostin antibodies
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
RU2015130100A (ru) TNF-альфа антиген-связывающие белки
JP2012504955A5 (enExample)
JP2022512704A5 (enExample)
JP2012504634A5 (enExample)
JP2020502261A5 (enExample)
PE20221151A1 (es) Anticuerpos anti-cd96 y sus metodos de uso
JP2025509266A5 (enExample)
JP2024507948A5 (enExample)